|
|
Post by mnkdfann on May 24, 2019 11:44:49 GMT -5
|
|
|
|
Post by mnkdfann on May 23, 2019 21:46:40 GMT -5
No ads for me either. You must be special.  |
|
|
|
Post by mnkdfann on May 22, 2019 20:13:33 GMT -5
Start Pos. Driver Manufacturer May 20 May 13 April 16 6 Will POWER Chevy 7-1 8-1 7-1 8 Josef NEWGARDEN Chevy 8-1 8-1 7-1 9 Alexander ROSSI Honda 8-1 8-1 8-1 18 Scott DIXON Honda 12-1 10-1 8-1 22 Ryan HUNTER-REAY Honda 20-1 12-1 10-1 1 Simon PAGENAUD Chevy 7-1 12-1 10-1 12 Helio CASTRONEVES Chevy 14-1 12-1 12-1 32 James HINCHCLIFFE Honda 40-1 16-1 14-1 10 Marco ANDRETTI Honda 20-1 18-1 16-1 2 Ed CARPENTER Chevy 8-1 18-1 16-1 16 Tony KANAAN Chevy 25-1 25-1 20-1 29 Felix ROSENQVIST Honda 60-1 30-1 20-1 7 Sebastien BOURDAIS Honda 18-1 30-1 30-1 17 Graham RAHAL Honda 25-1 20-1 30-1 DNQ Fernando ALONSO Chevy n/a 25-1 30-1 14 Takuma SATO Honda 25-1 25-1 30-1 13 Marcus ERICSSON Honda 40-1 50-1 40-1 31 Sage KARAM Chevy 100-1 40-1 40-1 11 Conor DALY Honda 40-1 40-1 40-1 4 Ed JONES Chevy 20-1 50-1 40-1 28 Zach VEACH Honda 40-1 40-1 40-1 21 JR HILDEBRAND Chevy 60-1 50-1 40-1 24 Matteus LEIST Chevy 80-1 60-1 60-1 5 Colton HERTA Honda 12-1 25-1 60-1 26 Jordan KING Honda 100-1 60-1 60-1 19 Oriol SERVIA Honda 80-1 60-1 60-1 3 Spencer PIGOT Chevy 12-1 25-1 60-1 DNQ Max CHILTON Chevy n/a 60-1 60-1 15 James DAVISON Honda 100-1 100-1 100-1 23 Santino FERRUCCI Honda 200-1 200-1 100-1 20 Charlie KIMBALL Chevy 100-1 200-1 100-1 DNQ Patricio O'WARD Chevy n/a 40-1 100-1 25 Jack HARVEY Honda 200-1 100-1 300-1 27 Ben HANLEY Chevy 1000-1 500-1 300-1 33 Kyle KAISER Chevy 500-1 50-1 500-1 30 Pippa MANN Chevy 1000-1 500-1 500-1 Source: www.therxforum.com/showthread.php?t=1138246 |
|
|
|
Post by mnkdfann on May 22, 2019 15:43:46 GMT -5
When I spoke to Rose at the ASM, she wasn’t aware of the details/plan about the PR surrounding Indy and Connor, but said something was planned. IF Connor wins, then I bet there will be more than currently planned. Great points all of which mean that MNKD may not be sitting on their hands and we shouldn't assume so just because a story came out about another driver. Actually, we need to introduce Kimball to Afrezza  The opportunity isn't missed yet. So where is the "Let's talk about patients like Conor" pamphlet, to tie in with the INDY 500 marketing? Read more: mnkd.proboards.com/thread/6238/nate-on-twitter?page=29#ixzz5ogk1dWTA |
|
|
|
Post by mnkdfann on May 22, 2019 13:18:34 GMT -5
I'm no expert, but from what I see on the web Kimball is a far more popular driver than Daly. I'm sure that also ties into who gets articles written about them. He probably has a house and a family, a car he needs to insure and put gas in. Novo Nordisk offered him money correct? I'm not sure what point you are making. Yes, I already mentioned that Novo Nordisk is one of Kimball's main partners. |
|
|
|
Post by mnkdfann on May 22, 2019 13:09:36 GMT -5
Can we say with absolutely certainty that they haven't tried reaching out? Maybe the impetus came from the driver or owner and not the makers of FIASP, Novo Nordisk? We are assuming a lot, sometimes. I'm no expert, but from what I see on the web Kimball is a far more popular driver than Daly. I'm sure that also ties into who gets articles written about them. |
|
|
|
Post by mnkdfann on May 22, 2019 13:05:44 GMT -5
"Kimball uses Tresiba and Fiasp insulins, products from one of his racing sponsors, Novo Nordisk. “We’ve been working together on the Race With Insulin program for a total of 11 race seasons,” he said. “I spent two years representing them for Indy Lights, and this is our ninth season in IndyCar." Novo Nordisk is also a (the?) main partner of Kimball's: www.charliekimball.com/partnersUnfortunately, CD hasn't anything approaching that sort of history with Mannkind or Afrezza. (Didn't he recently tweet that he had just started using Afrezza, and he hasn't said much about it since?) Nor is CD's race record nearly as good as Kimball's. It's unfortunate, but IMO that all severely limits Mannkind promotional opportunities.
|
|
|
|
Post by mnkdfann on May 19, 2019 22:25:45 GMT -5
I thought afterwards that I could check for myself so I went and had a look at the India trials database ( ctri.nic.in for those who are interested) and there is nothing filed yet so I suspect we are some time away from clearance in India. I don't think the CGM part is going to happen looking at other insulin trials. That makes sense in a trial since you need everyone to be on the technology the end patients will be using so there are no hidden dependencies, and CGMs for Type 2s in India are not going to be common. Do the powers that be in America generally give credence to trials in other parts of the world, and in particular India? I mean, assuming the trial goes well, would the FDA allow the Afrezza label to be changed based on this new trial, and would the ADA be likely to change the SOC? |
|
|
|
Post by mnkdfann on May 19, 2019 21:18:42 GMT -5
Its my understanding they are repeating the Affinity 1 and 2 studies for India except with CGMs and proper titration this time. You can't ask for more than that. Things take time but in the interim Dr. Kendall will continue to lay the foundation with the lost studies with more to come at ADA2019. I expect the one study will show T2 progression stopped. Along with the 118 study that about covers all bases for T2s. Is there any way to be sure of those trials? I would have thought that Cipla would want to avoid using CGMs on cost grounds. Also since they are the equivalent of phase 3 trials they are usually very conservative with those because of the stakes (a bad trial and you cannot launch the drug, whereas a bad result in a later trial is just inconvenient). In the last earnings call (May 7), Mike talked about the trials in India. He did not mention CGMs. In fact, as I understand it, he said the design was still being discussed. Of course, he may have mentioned CGMs elsewhere, I dunno. Sounds like the trial details are still a work in progress, though. seekingalpha.com/article/4261036-mannkind-corporation-mnkd-ceo-michael-castagna-q1-2019-results-earnings-call-transcript?part=singleMichael Castagna Yes. We believe it will be a few hundred patients, type II, and we're literally discussing as we speak. We're trying to get to better dosing in type II. We know from our Phil Levin study that will be coming out that the dosing in that was a way to standardize insulin titration and that's a big focus for us, is to make it very easy for prescribers to titrate patients who are naive to insulin or switching over to insulin. And I think that's the beauty of the Indian trials, we will be able to do a study probably the way we wish we could have done six, seven years ago on our last study with proper dosing and proper titration, because we know in that particular original pivotal trial, it took docs about 12 weeks to titrate up to the effective dose and even then we'd say it wasn't effective, because they had to stop titrating at the end of that period. We're trying to not repeat those mistakes in the Indian design and so far, we feel very good with our partner Cipla in that trial design and execution. We will be ready to start that trial. |
|
|
|
Post by mnkdfann on May 18, 2019 20:29:19 GMT -5
His previous best starting position at the Indy 500 was 23rd in 2015. So starting as 11th is a big improvement.
|
|
|
|
Post by mnkdfann on May 17, 2019 12:10:16 GMT -5
|
|
|
|
Post by mnkdfann on May 16, 2019 18:18:32 GMT -5
AMSL has about 80 people and revenue of $16M per qtr. This sounds like another BIOMM although at least this one doesn't make insulin. Oh, and they are the Tandem pump distributor in Australia. If a small company has an opportunity to secure exclusive regional rights to something for (apparently) next to nothing, well, why not? If and when Afrezza takes off in the U.S. and Australians are clamoring for access to it, AMSL will be golden. Until then, I'm not sure that AMSL will have wherewithal or desire to do much with the rights. |
|
|
|
Post by mnkdfann on May 16, 2019 18:04:48 GMT -5
From ST (BigPharmaBull) emailing Castagna about the deal...  Apparently this is the email he sent, that garnered the reply above.  |
|
|
|
Post by mnkdfann on May 16, 2019 15:22:58 GMT -5
Is Australia a public pay market or a socialized market? Socialize just may be easier to get penetration if the product is priced right to the Australian government. "Health care in Australia is delivered as a mixed system: universal health care (public) and private providers (insurance). Most health care is provided publicly (public hospitals and primary health care such as general practitioners), with the remaining provided by the private sector (private hospitals, allied health care such as physiotherapy and dental)." |
|
|
|
Post by mnkdfann on May 16, 2019 15:16:56 GMT -5
|
|
The opportunity isn't missed yet.
